11. U.S. Patented Drug Tariffs: Implications for India\'s Pharma Sector

• Targeted Trade Barriers: U.S. President Donald Trump has signed an executive order imposing a 100% ad valorem duty on specific patented pharmaceuticals and associated active ingredients. This move follows a Section 232 investigation initiated in May 2025, which identified heavy reliance on foreign drug supplies as a potential national security risk. • India’s Shield of Generics: According to the Global Trade Research Initiative (GTRI), India remains \'more or less shielded\' from this tariff hike. This is because the Indian pharmaceutical industry primarily exports low-cost generic medicines to the U.S., whereas the new tariffs specifically target high-cost \'patented\' drugs. • Dominance in the U.S. Market: India’s pharmaceutical exports to the U.S. reached $9.7 billion in 2025. India provides approximately 40% of the generic drug volume consumed in the U.S., making it an indispensable partner for the American healthcare system\'s cost-containment efforts. • National Security vs. Trade: The U.S. invocation of Section 232—traditionally used for steel and aluminum—highlights a growing global trend of \'securitizing\' supply chains. By labeling drug dependency a security threat, the U.S. seeks to incentivize \'reshoring\' or \'friend-shoring\' of critical medicine manufacturing. • Impact on Innovation and R&D: While generic manufacturers are safe, the 100% tariff could impact Indian firms that have recently ventured into \'New Chemical Entities\' (NCEs) or patented specialty drugs. It creates a high entry barrier for Indian innovation in the premium U.S. pharmaceutical segment. • Potential for Supply Chain Realignment: Although India is currently protected, the move signals a volatile trade environment. It emphasizes the need for Indian pharma to further diversify its export destinations and strengthen its backward integration to reduce dependence on Chinese APIs (Active Pharmaceutical Ingredients). Important Keypoints & Policy Framework • Section 232 of the Trade Expansion Act (1962): A U.S. law that allows the President to impose restrictions on imports if they are deemed a threat to national security. • \'Pharmacy of the World\': A moniker for India due to its status as the largest provider of generic drugs globally, accounting for 20% of global supply by volume. • API Dependency: Despite finished dose dominance, India still imports a significant portion of its APIs from China, which remains a strategic vulnerability in the global pharmaceutical value chain. Constitutional & Legal Context • Article 301: While this pertains to trade and commerce within the territory of India, the spirit of \'freedom of trade\' guides India’s objections to arbitrary international trade barriers at the WTO. • Patents Act, 1970 (India): The legal framework that transitioned India from \'product patents\' to \'process patents\' and back to \'product patents\' (post-2005 TRIPS compliance), facilitating the rise of the generic industry. • TRIPS Agreement: The WTO\'s Trade-Related Aspects of Intellectual Property Rights, which balances the protection of patented drugs with the public health necessity of generics. Key Definitions • Ad Valorem Duty: A tax based on the assessed value of an item (in this case, 100% of the drug\'s price) rather than on a fixed fee per unit. • Patented Drugs: Medicines protected by a patent, granting the inventor exclusive rights to manufacture and sell the drug for a specific period (usually 20 years). • Generic Medicines: Pharmaceutical products that are chemically identical to branded drugs but are sold under their chemical names at a much lower cost after the original patent expires. Conclusion: The imposition of 100% tariffs on patented drugs by the U.S. is a clear manifestation of \'economic nationalism.\' However, India’s strategic positioning as a provider of \'affordable healthcare\' through generics acts as a natural hedge against such protectionist measures. While the immediate fiscal impact is negligible, the long-term lesson for the Indian pharma sector is to accelerate the \'Production Linked Incentive\' (PLI) schemes to ensure self-reliance in the entire value chain, from raw materials to patented innovation. UPSC Relevance • GS Paper II (International Relations): Effect of policies and politics of developed and developing countries on India’s interests; Indian Diaspora and their role in the U.S. healthcare sector. • GS Paper III (Economy): Changes in industrial policy and their effects on industrial growth; Intellectual Property Rights (IPR) issues; Science and Technology- developments and their applications. • Prelims: Understanding Section 232, the difference between generic and patented drugs, and India\'s pharmaceutical export statistics.